PHAR: Joenja pediatric approval and the evidence bridge in APDS

September 11, 2026: what the FDA approved

FDA approved Joenja tablets for children aged 4–11 with activated PI3Kδ syndrome (APDS) who weigh at least 27 kg. This is an actual pediatric indication expansion, not a submission, acceptance or expected review date. Pharming is the sponsor and is listed on Nasdaq as PHAR. This independent History record documents the new age group without replacing the original 2023 approval or implying approval in common variable immunodeficiency (CVID). [1] [2] [10]

The central regulatory bridge is efficacy in the older randomized population plus pediatric exposure and safety. FDA identifies eight children receiving the recommended weight-based regimen in LE3301; this is not the entire 21-child pediatric research cohort. The current FDA action notice and dated sponsor announcement establish occurrence. The Drugs@FDA history retrieved for this review still displayed the 2023 original approval and 2025 supplement; the new action letter and FDA-hosted September label were not recovered, so their detailed conditions are not asserted.

Biology / Target: restoring signaling balance

APDS links pathogenic PIK3CD or PIK3R1 variants to excessive PI3Kδ signaling, disturbed lymphocyte maturation and lymphoproliferation. Recurrent infection can coexist with enlarged lymph nodes and spleen: more lymphoid tissue does not imply more effective immune protection. Leniolisib inhibits PI3Kδ, addressing the signaling abnormality rather than replacing immunoglobulin directly. Molecular diagnosis matters because the evidence is specific to this genetically defined disease. [1] [4] [11]

Interpretation: smaller nodes and a larger naïve-B-cell fraction provide complementary evidence of biological activity, but neither directly measures infections prevented, hospitalizations avoided or lymphoma-free survival. A percentage of naïve B cells is a cell-population proportion, not a patient response rate. The short randomized observation period and selected analysis populations limit what can be concluded about long-term clinical outcomes.

Molecule / PK–PD and pediatric dosing

The randomized regimen was oral leniolisib 70 mg twice daily. Pediatric development used weight-adjusted dosing to bridge exposure, rather than assuming a fixed adult dose would suit every child. FDA reports no clinically significant pharmacokinetic difference between the younger and older populations at the evaluated regimens. This supports the bridge; it does not establish a pediatric dose-response curve or an exposure threshold that guarantees individual benefit. [1] [5] [8]

The September sponsor label gives 40 mg twice daily at 27–<38 kg, 50 mg at 38–<45 kg and 70 mg at ≥45 kg for ages 4–<12. These are labeled regimens, distinct from the investigational 20–70 mg twice-daily doses made with 10/30 mg tablets in LE3301. The retrieved label contains broken cross-references and an older-age “any weight” row despite an indication-level ≥27 kg restriction; this report does not resolve that inconsistency or extend the pediatric approval below 27 kg.

Prior clinical evidence: Study 2201

NCT02435173 included a 12-week blinded, randomized, placebo-controlled part: 21 participants received leniolisib and 10 placebo, a 2:1 allocation; the design targeted 30 and actually enrolled 31. Participants were at least 12 years old with a confirmed APDS-associated variant. Background glucocorticoids and immunoglobulin replacement were present in both arms. The day-85 coprimary outcomes examined log10-transformed lymph-node sum of products of diameters (SPD) and the percentage of naïve B cells. [3] [4] [11]

Both prespecified primary tests were significant. The table uses the FDA label/snapshot analysis, not a mixture of publication estimates and regulatory denominators. A −0.25 log10 contrast is not a 25% shrinkage estimate. Similarly, 37.30 is a percentage-point contrast in cell composition, not a 37.30% relative improvement in infection outcomes. No patient-level clinical benefit can be reverse-calculated from these biomarker effects.

Analysis populations, missing data and interpretation

The primary estimands concern between-group mean changes within the pharmacodynamic analysis sets. They are not unrestricted intention-to-treat estimates for every randomized patient. Two participants per arm were excluded for protocol deviations. The node analysis also excluded one active participant with complete resolution of the index lesion identified at baseline. The B-cell analysis excluded participants with baseline fractions ≥48%, plus five active participants without day-85 data and one without a baseline measurement. These exclusions must not be described collectively as treatment dropout. [3] [4]

FDA adjusted for baseline measurements, glucocorticoids and any immunoglobulin replacement; the original SAP had specified intravenous IgG, and the review explains the broader covariate. Its conservative placebo-mean imputation sensitivity analysis included 14 active and five placebo participants, yielding a 27.38-point contrast (95% CI 7.14–47.62; p=0.01). That supports robustness to this particular assumption, not every possible missing-data mechanism. Both coprimary endpoints were required at two-sided 0.05; secondary and subgroup findings do not inherit confirmatory status automatically.

LE3301: the full pediatric cohort and regulatory subset

LE3301 (NCT05438407) was an international open-label, single-arm study in genetically confirmed APDS, ages 4–11. The retrieved registry specifies baseline weight ≥13 and <45 kg, measurable nodal disease, and washouts for mTOR/PI3K inhibitors and B-cell depletion. It still carries estimated enrollment of 15 in its May 6, 2026 version; the completed research cohort reported at CIS 2025 actually comprised 21. Estimated November/December 2026 completion fields are not dates of efficacy disclosure. Full registry-history reconciliation remains outstanding. [1] [6] [8]

At 12 weeks all 21 children completed treatment; endpoint-available counts were smaller and varied by measurement. The reported improvements are within-person changes without a concurrent control. The abstract does not provide a complete SAP, multiplicity procedure or an explanation for every unavailable measurement. The eight-child regulatory exposure subset must therefore remain separate from the 21-child efficacy/safety presentation, and neither may be relabeled as a pediatric randomized trial.

May 2026 extension: a separate follow-up version

Twenty of the original 21 children entered the extension. The May 1, 2026 abstract reports median treatment exposure of 51 weeks (range 18–64), with safety as the primary endpoint and no formal statistical hypotheses. Day-252 observations support persistence of activity in continuing participants, but selection into follow-up and the absence of placebo limit causal interpretation. This is longitudinal follow-up of the same cohort, not independent replication. [7]

B-cell marker definitions and available sample sizes differ across the reports, so their means are not plotted as one interchangeable series. The published extension abstract also reports a mean naïve-B-cell change that is not the simple difference between its displayed baseline and follow-up means; without matched individual records, this report does not “correct” that value by subtraction.

Safety: denominators and follow-up boundaries

FDA review Table 43 provides the randomized safety comparison below. The original publication reported no deaths through 30 days after trial end; the FDA review includes a later placebo follow-up death and a separate active-treatment extension death. Those statements concern different observation boundaries. A nonfatal SAE and a later fatal event may involve the same person, so the two rows must not be added to estimate unique patients with any SAE. [4] [5] [6] [7] [11]

The September sponsor label reports ANC 500–1500 cells/µL in 7/21 older participants and 5/8 children in the regulatory subset, with no ANC below 500 or associated infection reported. These populations and exposure periods are not interchangeable, so no pediatric-versus-adult comparative safety chart is drawn. Label warnings include embryo-fetal toxicity, reduced effectiveness of live attenuated vaccines and postmarketing hypersensitivity including anaphylaxis. Strong CYP3A4 inhibitors and strong/moderate inducers can alter exposure; moderate/severe hepatic impairment is not recommended.

Randomized TEAE comparison

These bars reproduce the any-TEAE row above, using patients with at least one event rather than event counts. The numerical difference is descriptive; 21 versus 10 participants cannot establish equivalence, and this chart does not compare the randomized trial with the pediatric extension. [4]

Capital structure / Management and research execution

Pharming’s July 30 report identifies Fabrice Chouraqui as CEO and reports $159.5 million of cash, cash equivalents, restricted cash and marketable securities at June 30, 2026. This combined figure must not be labeled wholly unrestricted cash. First-half operating cash use was $7.7 million. The figures inform capacity to maintain follow-up and additional trials; they do not establish a precise runway because working capital, restricted balances and future commitments matter. [9]

The same update anticipates two Phase II leniolisib readouts in broader primary immunodeficiencies, including CVID, in Q4 2026. Those are separate research questions and require their own event records and evidence review; this APDS approval cannot validate them. Current diluted share count, convertible-debt terms and all trial commitments were not fully extracted here, so no per-share calculation or financing sufficiency claim is made. The execution priority is complete pediatric follow-up and transparent reporting across distinct indications.

Sources / References

1. FDA · Pediatric Joenja action, listed September 11, 2026 · retrieved September 13
2. Pharming · FDA pediatric approval announcement · September 11, 2026
3. FDA · Joenja original approval trial snapshot · March 24, 2023 approval
4. FDA · NDA 217759 multidisciplinary review · 2023 · Tables 18, 43, 44 and 46
5. Joenja · Sponsor-hosted US prescribing information · revised September 2026 · retrieved September 13
6. Rao et al. · Pediatric 12-week primary and safety outcomes · CIS 2025 abstract 6
7. Rao et al. · Pediatric extension interim results · CIS 2026 abstract 217 · May 1, 2026
8. ClinicalTrials.gov · NCT05438407 / LE3301 · record posted May 6, 2026 · retrieved September 13
9. Pharming · Second quarter and first half 2026 financial results · July 30, 2026
10. Drugs@FDA · NDA 217759 action history · retrieved September 13, 2026
11. Rao et al. · Randomized leniolisib trial · Blood 2023;141:971–983 · published online November 21, 2022